Testosterone Booster: Effects & Evidence – What’s Actually Proven

Testosterone boosters sound like an easy solution: buy a supplement, raise hormone levels, improve energy. The reality is much less convenient. The most important systematic analysis of “testosterone boosters” has a sobering core message: overall, there is no convincingly consistent increase in serum total testosterone that can be cleanly demonstrated across products. In many cases, diagnostics and lifestyle levers are the better, more measurable path.

Real starting point: When “boosting” makes sense at all

“Boosting” is only a sensible idea if there is a specific suspicion of clinically relevant low testosterone and you’ve confirmed it with proper diagnostic testing beforehand. Without reliable measurement, “boosters” quickly become an expensive hope-combination, because symptoms like fatigue, low drive, or reduced libido are extremely nonspecific. That’s the key point: the likelihood is high that the same complaints can also result from sleep loss, overweight, high alcohol intake, psychological stress, or other conditions.

Before you buy anything, the foundation needs to be right: Serum testosterone should be measured only when there is a concrete suspicion. This isn’t a minor detail. If you measure values “somehow” repeatedly or without context, results may fluctuate randomly or reflect a temporary situation. It’s also important to interpret the measurement within the right framework: testosterone has circadian fluctuations, and the state (e.g., acute illness, severe sleep deprivation, or very high alcohol intake in the days before) can influence levels. That’s exactly why a repeat measurement in a medical context is often a prerequisite to even determine whether the value is truly “low.”

The second lever is decoupling “numbers” and “how you feel.” Even if lab values are low, the therapeutic priority isn’t automatically a supplement. Many causes with potential relevance to testosterone are lifestyle-driven. If you chronically sleep poorly or are significantly overweight, adjustments here can already provide more than booster products. But if there is a genuine target value “below normal,” then you need medical evaluation: first identify causes, then choose the appropriate intervention. That’s what distinguishes boosters from targeted testosterone therapy—and that’s exactly where the booster idea tends to fail in practice.

If you’re unsure how strongly sleep and circadian rhythm can affect this, a good entry anchor is: Sleep & Testosterone: Effects, Evidence & What’s Actually Proven.

Evidence hierarchy: What the studies actually say

The core question is: Do “testosterone boosters” increase serum total testosterone? To answer this, you need studies that directly measure the endpoint (hormone in blood)—and do so in a way that allows comparison across products. In your study list, this central question is addressed most cleanly by a systematic review: (Morgado et al., 2024, PMID 37697053).

Why is that so important? A systematic review combines all available evidence that meets defined inclusion criteria. Methodologically, it sits above individual RCTs or smaller studies because it tries to determine the overall direction of the signal—and it also makes heterogeneity visible (differences in product, dose, population, and study design). This is especially crucial for dietary supplements, because products are rarely identical. Even if labels promise “testosterone boosters,” the actual ingredients, combinations, dosages, and study conditions often differ substantially.

Many other works in your list, by contrast, don’t provide a direct answer to “does it work reliably as an OTC booster product?” For example, trend or utilization studies on testosterone replacement therapy (Kuo et al., 2026, PMID 41505196) are primarily descriptive—they don’t address the effect of specific OTC booster products on serum total testosterone. Likewise, reviews or frameworks on “androgen adequacy vs inadequacy” or on the link between testosterone and prostate cancer (Morgentaler et al., 2026, PMID 41529181) are not efficacy studies of dietary supplements. They address rather safety and interpretation questions around testosterone therapy, not the booster question.

The same applies to studies on progression in prostate cancer under active surveillance (Lawen et al., 2026, PMID 41662578): these are observational, patient-based analyses and don’t answer causally whether boosters increase the hormone in blood. And studies on “strategic” athletes (Lazarev et al., 2026, PMID 41630126) or case reports (Akaltun et al., 2026, PMID 41804739) are also not methodologically suitable to infer a consistent booster effect on total testosterone.

This doesn’t mean those papers are worthless—they help with risk framing, context, and mechanisms. But for the question “actually effective as a booster,” the evidence situation is clear: you need to judge the claim against studies that directly address the endpoint and are methodologically comparable. That’s exactly what makes the systematic review so central.

What’s proven: Systematic review on “testosterone boosters” and total testosterone

What’s proven? The systematic review (Morgado et al., 2024, PMID 37697053) aggregates studies on whether “testosterone boosters” increase serum total testosterone. The review’s central conclusion is: Overall, the data do not support a convincing, consistent increase in serum total testosterone from such products. That leaves practical expectations for boosters—if anything—unclear and not robust across different products.

It’s important how you interpret this statement: “No convincing, consistent increase” does not automatically mean no product ever produces any effect. It means that the overall balance of the evidence doesn’t support it—i.e., the effect isn’t reliably reproducible or the results are too heterogeneous. For informed consumers, this is the relevant level: you don’t want an effect that appears by chance in a single small trial; you want a reliable direction that holds up in real life.

A second point: a systematic review doesn’t just assess direction, it also evaluates the quality and consistency of the evidence. For supplements, this is often a bottleneck. Even if individual trials show “positive” results, differences in formulations, different starting values in participants, or methodological variation can prevent the overall signal from stabilizing. That stability assessment is built into (Morgado et al., 2024, PMID 37697053).

What does that mean for your purchasing decision? If you see “testosterone boosters” as a replacement for diagnostics and medical evaluation, the scientific rationale isn’t strong. If you truly have a low value, an established medical strategy would be more plausible than an OTC booster. “If anything, effects (if present) are unclear” is the honest conclusion that fits the review—not a marketing claim.

If you want to understand why endpoints like “total testosterone” are not automatically the same as “effects in the body,” it also helps to look at the evidence strength of individual lifestyle levers: Understanding effect sizes: Effects & evidence for 1–2 levers. In that plan, boosters would be at most a side topic, not the main strategy.

What doesn’t fit: Therapy and cancer evidence are not booster evidence

In many discussions, testosterone studies get mixed together: what is about safety or disease course under testosterone therapy is then incorrectly used as evidence that “boosters work.” Your list includes several papers that address the testosterone topic but don’t directly answer the booster question.

First, there is the framework for contextualizing testosterone in relation to the prostate: (Morgentaler et al., 2026, PMID 41529181) discusses the argument that testosterone doesn’t “drive” prostate cancer and describes a new framework for “androgen adequacy vs inadequacy.” This is interesting for a safety perspective on testosterone—but it’s not a study testing whether OTC supplements significantly increase serum total testosterone, and it doesn’t provide a causal booster effect.

Second, there are observational data on patient trajectories in prostate cancer under active surveillance: (Lawen et al., 2026, PMID 41662578) examines associations between low testosterone and progression. This also doesn’t answer the causal booster question: an observed association in a patient group with prostate cancer doesn’t mean you can “follow along” by using OTC boosters. Additionally, it’s not about standardized supplement effects; it concerns clinical scenarios.

Also (Kuo et al., 2026, PMID 41505196) is designed as a utilization/trend study for testosterone replacement therapy claims in Medicare Part D. Even if such data show how often testosterone therapy is claimed or how trends develop, that is not evidence that boosters as dietary supplements reliably achieve the same hormonal effects.

Finally, “athlete strategies” and related literature (Lazarev et al., 2026, PMID 41630126) or individual case reports (Akaltun et al., 2026, PMID 41804739) likewise do not provide stable efficacy evidence for OTC boosters. A case report can suggest possible side effects or associations, but it isn’t a substitute for controlled efficacy data at the endpoint “total testosterone.”

In short: therapy and cancer evidence primarily clarifies safety/interpretation/clinical framing. For “does it work as a booster?” you need endpoint evidence—and according to (Morgado et al., 2024, PMID 37697053), the current evidence base is overall not convincingly and consistently supportive.

Lifestyle before supplements: Levers that more often produce measurable hormone differences

If you want to pursue the goal of “more testosterone effect” realistically and scientifically, you should first target lifestyle factors that have the highest likelihood of producing measurable differences—precisely the type of precision booster studies often fail to deliver. While your study list doesn’t provide a direct, quantitative “testosterone + X from intervention Y” number across all details, the methodological principle remains: lifestyle changes influence multiple biologically relevant mechanisms at once (energy balance, inflammation, stress axes, sleep rhythm, body composition). Supplements, on the other hand, often have fewer broad and less consistent effects—and that is reflected in the overall booster evidence.

A particularly plausible and often practical lever is sleep. Hormonal rhythms follow daily structures, and sleep loss can affect endocrine axes. If you intervene here concretely (duration, regularity, sleep quality), you typically get an intervention that is more consistently visible in the lab and in symptoms than a product whose composition and study settings vary. If you want to discuss sleep as a priority, that’s already linked above: Sleep & Testosterone: Effects, Evidence & What’s Actually Proven.

The second major block is physical activity, especially resistance training with progressive overload. The connection between training, body composition, and endocrine signaling is biologically plausible and often measurable in practice (e.g., via fat mass, lean muscle mass, and metabolic health). Many booster studies, by contrast, show no robust, reproducible rise in serum total testosterone—consistent with (Morgado et al., 2024, PMID 37697053). So if your goal is to optimize the “likelihood of effect,” the focus should be first on training and energy/weight regulation.

Diet and alcohol are additional levers: high alcohol intake can disrupt endocrine and metabolic functions, and overweight changes energy balance and inflammation levels. These aren’t “boosters,” but they are often the reason testosterone is suppressed in the first place—and that’s why a booster without addressing the underlying cause can end up having little to no impact.

If you still want to use a product as an add-on, it should have a clearly secondary role in your plan. The scientifically clean order is: improve sleep and training, control diagnosis/endpoints, then—if there’s still a need and a sensible context—consider supplements. This helps you avoid confusing symptom management with lab optimization.

When certain ingredients are theoretically plausible—and why that doesn’t automatically mean “effective”

Ingredients can be theoretically interesting even if the overall evidence balance for “testosterone-boosting supplements” as a class isn’t convincing. One example from your list is the review on Withania somnifera (Ashwagandha) and Trigonella foenum-graecum (fenugreek) as possible components of “testosterone-boosting supplements”: (Skrzypiec-Spring et al., 2025, PMID 38628109). There, possible clinical implications are discussed in the context of “testosterone boosting.”

Important: A literature discussion like this is not the same as robust evidence that these ingredients consistently increase serum total testosterone in humans. It can offer plausible mechanisms, preliminary findings, or derived hypotheses. But the booster question requires studies that measure the exact endpoint and show similar results across robust study designs. Exactly this overall consistency is missing, according to (Morgado et al., 2024, PMID 37697053) for “testosterone boosters” as a category.

The same applies to mechanism-focused reviews. For example, (Zhou et al., 2026, PMID 41714893) discusses “NAD⁺-Sirtuins-Signaling” in the context of male reproductive aging and “restoring” such signals. This direction is scientifically interesting, but: mechanism and aging relevance are not a guarantee of a measurable, clinically meaningful testosterone effect from a specific supplement. Even if a pathway is affected, it may not change the “total testosterone” endpoint at all—or only in an unreliable way—and it can strongly depend on the starting condition.

That leads to a practical guideline: if you’re thinking about ingredients, first check whether your evidence base contains studies that (a) measure the total testosterone endpoint in blood, (b) include an appropriate comparison group, and (c) show results not only in narrow subgroups or only with very specific baseline values. If these conditions aren’t met, it stays at “theoretically plausible.”

So the honest framing is: ingredient reviews can help you formulate questions and understand products, but they don’t replace evidence that a product reliably changes the relevant lab value as a booster. If your goal is “testosterone levels” specifically, diagnosis and the general lifestyle strategy are always the better starting point—because they address not only mechanisms but also frequently the real-world bottleneck.

Study overview: What fits your list regarding booster effects, diagnostics, and risks

For your list, mapping is relatively straightforward: Direct booster effects on serum total testosterone are mainly covered by (Morgado et al., 2024, PMID 37697053)—and there the overall balance shows no convincing, consistent increase. Everything else mainly adds context on therapy, prostate cancer, mechanisms, or rare individual events.

How do you use this overview practically? If your goal is “higher serum total testosterone,” then your most important evidence is (Morgado et al., 2024, PMID 37697053). Everything that primarily discusses therapy, prostate cancer, or mechanisms does not reliably answer whether over-the-counter booster products as a class work.

For risks, something similar applies: a case report (Akaltun et al., 2026, PMID 41804739) can draw attention to possible neuropsychological events in a very specific setting. But such data are not sufficient for a general safety assessment. Without RCTs or large systematic safety data, robust risk assessment remains limited. The correct interpretation is: “possible indication, but not generalizable.”

If you want to proceed diagnostically, the central building block remains: measure serum testosterone purposefully and interpret it in context—then decide on interventions. If there are existing prostate findings or ongoing conditions, you should get medical clarification, because in that scenario the question of “safety and strategy” dominates over the “booster” question. The studies that cover prostate contexts (Morgentaler et al., 2026, PMID 41529181; Lawen et al., 2026, PMID 41662578) are not booster efficacy studies, but they show that clinical framing is not trivial.

What to take away from this

• The best available overall balance on the booster question is limited: (Morgado et al., 2024, PMID 37697053) finds no convincing, consistent increase in serum total testosterone from “testosterone boosters.”
• Therapy and cancer evidence (e.g., prostate frameworks or active surveillance) does not automatically answer whether OTC boosters increase the hormone.
• Ingredient reviews like those involving Withania somnifera and Trigonella provide plausibility, but they are not a replacement for consistent RCT endpoint data on total testosterone (Skrzypiec-Spring et al., 2025, PMID 38628109).
• When making real decisions, prioritize diagnostics and lifestyle levers (sleep, exercise, body composition, alcohol/diet) rather than planning “boosters” as the main strategy.